IL-33 levels are increased in the serum of lung and gastric cancer patients and correlate with disease stage, and expression levels of IL-33 and ST2 correlate with tumor grade and inferior survival of glioblastoma patients, suggesting that IL-33 may be a negative prognostic marker for these types of cancer [77,78,79]. This evidence concerns the gene IL33 and gastric cancer.